Evidence map›Paper›PMID 41994131›Full record

ArticleResearch square2026

X-ray Co-crystal Structure of a Novel Pseudomonas aeruginosa DXPS Inhibitor Reveals an Unusual Allosteric Binding Pocket.

Anna Hirsch, Antoine Lacour, Rawia Hamid, Noah Smith, Lydia Krammer, Jörg Haupenthal, Prateek Raj, Sidra Eisa, Dirk Heinz, Mostafa Hamed and 2 more

Abstract readPreprint
In one paragraph

Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Anna HirschSaarland University, HIPS, DZIF.ORCID 0000-0001-8734-4663
Antoine LacourHelmholtz Institute for Pharmaceutical Research Saarland (HIPS).ORCID 0000-0002-0051-8710
Rawia HamidHelmholtz Institute for Pharmaceutical Research Saarland (HIPS).
Lydia KrammerJohns Hopkins University School of Medicine.
Jörg HaupenthalHelmholtz Institute for Pharmaceutical Research Saarland (HIPS) - Helmholtz Centre for Infection Research (HZI).
Prateek RajHZI.
Sidra EisaHelmholtz Institute for Pharmaceutical Research Saarland (HIPS).ORCID 0009-0003-0082-9871
Dirk HeinzHelmholz Centre for Infection Research (HZI).ORCID 0009-0006-0514-1728
Mostafa HamedHelmholtz Institute for Pharmaceutical Research Saarland (HIPS).
Eleonora DiamantiHelmholtz Institute for Pharmaceutical Research Saarland (HIPS).
Caren Freel MeyersJohns Hopkins School of Medicine.ORCID 0000-0003-1458-0897

Funding

Biochemistry, Cellular and Molecular Biology Program: JHU BioGREAT (Biomedical Graduate REsiliency & Adaptability Training)T32GM144272 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI Takanari Inoue · 2022 to 2026
$5.4M
The Chemistry-Biology Interface Program at Johns Hopkins UniversityT32GM149382 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI STEVEN E ROKITA · 2023 to 2026
$1.4M
NIGMS NIH HHS T32 GM144272NIGMS NIH HHS T32 GM149382
6 · The paper itself

Abstract

The enzyme 1-deoxy-D-xylulose 5-phosphate synthase (DXPS) catalyzes the first and rate-limiting step of the methylerythritol 4-phosphate (MEP) pathway, representing a promising target for novel anti-infective agents. Given its essential role in the survival of Gram-negative pathogenic bacteria and its absence in humans, drug-discovery efforts to advance our understanding of this enzyme are urgently needed. Here, we unraveled a novel druggable allosteric pocket in DXPS, unexpectedly revealed through co-crystallization of tool compound

Identifiers

PMID41994131
PMCPMC13082120

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.